Introduction:
Viral infections undoubtedly constitute the biggest pandemic threat in the modern era due to lack of ‘broad-spectrum’ antiviral agents. Whereas, the threat is much less in case of bacteria in spite of their more virulent natrure, due to development of multiple novel antibacterial drugs.[1] The major concern in antiviral drug development is to preserve the host cell function normal, though the viruses utilise host cell machinery due to their obligate parasite nature. Other obstacles are differences between RNA and DNA viruses, vastly different virally encoded proteins across viral families, single or double strand genomic structure and cytoplasmic or nuclear replications cycles. Present approach remains aiming finding treatments for specific individual viruses of concern rather than their families. In most of the cases of novel viral epidemic, supportive care remains the mainstay of therapy rather than antiviral drug. So, development of novel broad spectrum antivirals is of utmost importance in present time.